PFIZER · Pfizer Ltd · Major Drugs
PFIZER · Pfizer Ltd · Major Drugs
As of 06 Nov close
52-week range
27.8% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 53 days old
Revenue (latest Q)
₹653 Cr
Revenue YoY
PAT YoY
+6.6%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
5.1
P/S (TTM)
7.2
Sector P/E
36.3
Dividend yield
+1.9%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| PFIZER (this stock) | 27.6 | 5.1 | +28.6% | +17.5% | 0.02 | +1.9% |
| Aurobindo Pharma | 24.7 | 2.9 | +10.6% | +9.8% | 0.21 | 0.0% |
| Neuland Laboratories | 64.3 | 12.6 | +18.0% | +21.4% | 13.9 | +0.2% |
| Unichem Laboratories | 10.7 | 1.3 | +13.2% | +11.2% | 0.18 | 0.0% |
Promoter
stable
FII
falling 1q
MF
12.68% (+1.16pp)
rising 1q
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
- loweconomictimes.indiatimes.com· 09 Oct 2026, 01:57 pmPidilite shares rise marginally as company appoints Amit Agarwal CFO-designate
- loweconomictimes.indiatimes.com· 29 Sept 2026, 05:46 pmMedico Remedies among 5 Healthcare stocks hitting 52-week low; slipped up to 48% in a month - New Bottoms
- unknownbusiness-standard.com· 10 Sept 2026, 10:56 amNovartis India zooms 51% in 3 days; what's driving the pharma stock?
- unknownthehindubusinessline.com· 09 Sept 2026, 09:28 pmNovartis-Pfizer trademark deal has opposite impact on their stock prices; Novartis India jumps 20% while Pfizer slips 3%
- lowlivemint.com· 01 Sept 2026, 04:41 pmSun Pharma signs deal with US government to reduce drug prices
- lowtimesofindia.indiatimes.com· 06 Aug 2026, 08:25 amTop stocks to buy today: Stock recommendations for August 6, 2026 - check list
- lowthehindubusinessline.com· 17 Jul 2026, 08:56 pmPfizer confirms it had temporarily suspended its Premarin brand of vaginal cream in India
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedPfizer Limited's FY2023-24 annual report highlights the company's focus on digital transformation, compliance, and corporate governance. The report notes the appointment of Mr. P. Rengan as Executive Director – Plant Operations and the resignation of cost auditors due to a partner's inheritance of company shares. The company has maintained strong financial controls, with no material changes affecting its financial position. The auditor's report did not contain any qualifications, reservations, or adverse remarks. The company is engaged in litigations with sales tax authorities and under the Drug (Prices Controls) Orders (DPCO), with significant amounts involved, though these are classified as contingent liabilities. The company has also been proactive in CSR initiatives and has a robust compliance framework in place.
- Appointment of Mr. P. Rengan as Executive Director – Plant Operations with a 5-year term.
- Resignation of cost auditors due to a partner's inheritance of company shares.
- No material changes affecting the company's financial position.
- Litigations with sales tax authorities and under DPCO with significant amounts involved, classified as contingent liabilities.
- Robust compliance framework and CSR initiatives.
Key takeaway: Pfizer Limited maintains strong corporate governance and compliance, with notable focus on digital transformation and CSR, though it faces contingent liabilities from ongoing litigations.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
No item of a kind that needs attention was stored for this company.
Internal Control Weakness
1 occurrenceEarlier (1-3 years ago)
The auditor identified a significant deficiency in the internal control related to the backup of the payroll software, which is part of the books of account.
Contingent Liability
3 occurrencesRecent (last 12 months)
As at 31 March 2026, the Company has pending litigations related to income tax, indirect tax, product pricing and other regulatory matters. The amounts involved are significant and require careful evaluation under Ind AS 37 and Ind AS 12.
Earlier (1-3 years ago)
The company has pending litigation with sales tax authorities for several financial years, at various stages and forums, related to non-submission of documentary evidence, legal questions, and disallowance by authorities.
The company has pending litigation with sales tax authorities for several financial years, which are at various stages and pending at different forums.
Statutory dues in dispute
3 occurrencesRecent (last 12 months)
The company has a pending dispute regarding statutory dues of Goods and Service Tax, Income-Tax, Duty of Customs or Cess, with an amount of ` in crore, and the dispute is pending at a forum.
Earlier (1-3 years ago)
The company has statutory dues under various tax acts (Income Tax, Customs, Excise) with amounts in dispute, pending before multiple forums including Assessing Officer, Commissioner of Income Tax, Appeals, Income Tax Appellate Tribunal, High Court of Bombay, and Supreme Court, covering multiple financial years.
The company has statutory dues under dispute with various authorities including Income Tax, Excise, and Customs, with amounts unpaid and disputes pending in multiple forums.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
2.0% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).